In a recent thread, retreating with Harvoni was mentioned for any treatment failures on Viekira Pak. There is a question mark over this.
At the recent EASL Meeting, a paper was presented dealing with the persistence of RAV's after failed Viekira Pak treatment. This is of particular interest for the Genotype 1a's.
The paper lists the RAV's found in treatment failures. As expected, the RAV's at the NS-3 site declined over time, and only 9% of RAV's were present at EOT +48 weeks. However, RAV's at NS-5A persisted and 96% were still present after EOT +48 weeks. From previous studies, these RAV's to Ombitasvir are similar to the RAV's associated with Ledipasvir.
What we need now is a similar paper detailing the RAV's associated with Harvoni treatment failures.
Thankfully the number of treatment failures will be small.
Hi all,
In a recent thread, retreating with Harvoni was mentioned for any treatment failures on Viekira Pak. There is a question mark over this.
At the recent EASL Meeting, a paper was presented dealing with the persistence of RAV's after failed Viekira Pak treatment. This is of particular interest for the Genotype 1a's.
The paper lists the RAV's found in treatment failures. As expected, the RAV's at the NS-3 site declined over time, and only 9% of RAV's were present at EOT +48 weeks. However, RAV's at NS-5A persisted and 96% were still present after EOT +48 weeks. From previous studies, these RAV's to Ombitasvir are similar to the RAV's associated with Ledipasvir.
What we need now is a similar paper detailing the RAV's associated with Harvoni treatment failures.
Thankfully the number of treatment failures will be small.
http://www.natap.org/2015/EASL/EASL_38.htm